CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Receives Average Rating of “Moderate Buy” from Analysts

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $9.5625.

Several equities research analysts have recently commented on the stock. Weiss Ratings lowered shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $5.00 to $9.00 in a research report on Tuesday, June 16th. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th.

CAMP4 Therapeutics Stock Down 1.8%

Shares of CAMP4 Therapeutics stock opened at $4.41 on Friday. The company has a market cap of $276.73 million, a price-to-earnings ratio of -1.90 and a beta of 0.27. The company’s 50 day moving average is $4.13 and its 200 day moving average is $4.35. CAMP4 Therapeutics has a twelve month low of $1.46 and a twelve month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The firm had revenue of $1.78 million during the quarter. Sell-side analysts expect that CAMP4 Therapeutics will post -0.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Andrew Schwab sold 400,000 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the sale, the director directly owned 2,033,270 shares of the company’s stock, valued at $8,214,410.80. This represents a 16.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kelly Gold bought 10,000 shares of the stock in a transaction dated Monday, August 31st. The shares were purchased at an average price of $3.96 per share, with a total value of $39,600.00. Following the completion of the transaction, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $39,600. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Corporate insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

Large investors have recently made changes to their positions in the business. Bank of America Corp DE bought a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $78,000. Trails Edge Capital Partners LP bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at approximately $8,446,935. Jupiter Topco LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $27,581,000. 5AM Venture Management LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $25,647,928. Finally, BlackRock Inc. bought a new position in shares of CAMP4 Therapeutics during the 2nd quarter valued at approximately $7,185,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.